OTCMKTS:SEOVF Sernova Biotherapeutics Q3 2026 Earnings Results & Report $0.08 0.00 (-0.37%) As of 10/9/2026 03:55 PM Eastern Sernova Biotherapeutics missed analyst earnings expectations in its Q3 2026 results, released September 10, 2026. The company reported EPS of -$0.01 versus the -$0.0050 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2026Report DateSeptember 10, 2026TimeBefore Market Opens Sernova Biotherapeutics EPS ResultsActual EPS-$0.01Consensus EPS -$0.0050Beat/MissMissed by -$0.0050One Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersSernova Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSernova Biotherapeutics' next earnings date is estimated for Friday, December 18, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sernova Biotherapeutics Q3 2026 Earnings FAQ Did Sernova Biotherapeutics beat earnings estimates for Q3 2026? Sernova Biotherapeutics (OTCMKTS:SEOVF) reported earnings of -$0.01 per share for Q3 2026, missing the consensus estimate of -$0.0050. The report was announced on Thursday, September 10, 2026. When is Sernova Biotherapeutics' next earnings date? Sernova Biotherapeutics' next earnings date is estimated for Friday, December 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sernova Biotherapeutics on the company's earnings history page. Sernova Biotherapeutics Earnings HeadlinesSernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical TrialOctober 5, 2026 | globenewswire.comSernova Biotherapeutics Inc (SVA)September 25, 2026 | ca.investing.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live. | Banyan Hill Publishing (Ad)Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity ConferenceSeptember 25, 2026 | globenewswire.comSernova Biotherapeutics Inc SEOVFMay 14, 2026 | morningstar.comMSernova Biotherapeutics: Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to ...March 4, 2026 | finanznachrichten.deSee More Sernova Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email. Email Address About Sernova BiotherapeuticsSernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical-stage biotechnology company developing regenerative medicine technologies designed to provide long-term treatment for chronic diseases. The company’s primary platform, the Cell Pouch System, is an implantable device intended to create a vascularized environment in the body where therapeutic cells can be placed and supported. Sernova has focused on cell-based therapies for conditions including type 1 diabetes, hemophilia A and thyroid disease. Its approach combines the Cell Pouch System with insulin-producing islet cells, blood-clotting factor-producing cells or other therapeutic cells, with the goal of restoring biological functions that are impaired by disease. The company has also explored technologies intended to protect transplanted cells from immune-system rejection and reduce or eliminate the need for chronic immunosuppressive drugs. Based in London, Ontario, Canada, Sernova has conducted research and clinical development activities in Canada and the United States. The company has been led by Dr. Philip Toleikis, who has served as president and chief executive officer. Its programs remain focused on advancing cell-based and regenerative therapies toward potential clinical applications.View Sernova Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
